 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
86 News |  |
| 12» |
- || lactulose / Generic mfg., Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, L-ornithine-L-aspartate / Generic mfg.
Review, Journal: Hepatic encephalopathy: risk identification and prophylaxis approaches. (Pubmed Central) - Mar 7, 2025
However, novel approaches like L-ornithine L-aspartate, albumin infusions, and antioxidants like resveratrol show promise in further improving outcomes by addressing underlying pathophysiological mechanisms, including systemic inflammation and gut dysbiosis...The future of HE management lies in personalized medicine, targeting specific inflammatory and metabolic pathways, with the potential integration of genetic manipulation. Continued research is essential to refine these strategies, ultimately aiming to improve the prognosis and quality of life for cirrhotic patients at risk of HE.
- | AlbuRx (human albumin) / CSL Behring, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Trial initiation date: Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (clinicaltrials.gov) - Mar 4, 2025
P=N/A, N=174, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
Continued research is essential to refine these strategies, ultimately aiming to improve the prognosis and quality of life for cirrhotic patients at risk of HE. Initiation date: Oct 2024 --> May 2025
- | lactulose / Generic mfg., Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, L-ornithine-L-aspartate / Generic mfg.
Journal: Unusual Presentation of Confusion: Hyperammonaemic Hepatic Encephalopathy Due to Intrahepatic Portosystemic Venous Shunt. (Pubmed Central) - Feb 26, 2025
Intrahepatic portosystemic venous shunts should be considered in the differential diagnosis of patients presenting with confusion or other unexplained neurological symptoms, especially in the presence of liver dysfunction. Early diagnosis and appropriate management are crucial for favourable outcomes.
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Clinical, Review, Journal: Hepatic encephalopathy: experimental drugs in development and therapeutic potential. (Pubmed Central) - Dec 20, 2024
Alternatives such as polyethylene glycol and L-ornithine L-aspartate have been effective in certain cases...Additionally, the multifactorial nature of HE, together with a high spontaneous response rate, complicates efforts to isolate treatment effects. Despite current limitations, ongoing research and technological advances hold promise for more effective and individualized HE treatments in the future.
- L-ornithine-L-aspartate / Generic mfg.
ARGININE GLUTAMATE INJECTION FOR THE TREATMENT OF MILD HEPATIC ENCEPHALOPATHY: AN OPEN LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2826;
Both arginine glutamate injection and L-ornithine-L-aspartate injection effectively alleviated clinical symptoms and reduced blood ammonia levels in patients with cirrhosis and mild HE, with the clinical improvement rate of arginine glutamate being non-inferior to that of L-ornithine-L-aspartate. Compared to L-ornithine-L-aspartate, arginine glutamate also achieved non-inferiority in reducing blood ammonia and improving number connection test scores, with no appreciable adverse effects.
- | AlbuRx (human albumin) / CSL Behring, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Trial initiation date: Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (clinicaltrials.gov) - Sep 26, 2024
P=N/A, N=174, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
Compared to L-ornithine-L-aspartate, arginine glutamate also achieved non-inferiority in reducing blood ammonia and improving number connection test scores, with no appreciable adverse effects. Initiation date: Jul 2024 --> Oct 2024
- | L-ornithine-L-aspartate / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Aug 19, 2024
P4, N=140, Recruiting, Sponsor: Ain Shams University
Initiation date: Jul 2024 --> Oct 2024 Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Review, Journal: Prophylaxis of hepatic encephalopathy: current and future drug targets. (Pubmed Central) - Aug 4, 2024
Rifaximin is equally effective as lactulose in managing hepatic encephalopathy and is better tolerated...L-ornithine L-aspartate and probiotics are also useful in the management of hepatic encephalopathy...Nutritional therapy and fecal microbiota transplantation are newer therapies for hepatic encephalopathy but the evidences are limited, more research is required to prove their efficacy. Involvement of hospital pharmacists, telemedicine, and providing education are also beneficial in managing hepatic encephalopathy.
- | AlbuRx (human albumin) / CSL Behring, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
New trial: Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=174, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- | levetiracetam / Generic mfg., carbamazepine / Generic mfg., L-ornithine-L-aspartate / Generic mfg.
Journal: From seizures to cognitive dysfunction: A case report of Fahr syndrome in an Afghan patient. (Pubmed Central) - Jun 21, 2024
Involvement of hospital pharmacists, telemedicine, and providing education are also beneficial in managing hepatic encephalopathy. This case underscores the importance of raising awareness among physicians, especially in areas with limited medical resources, about the significance of prompt diagnosis and appropriate symptomatic treatment in enhancing patient prognosis and quality of life.
- || L-ornithine-L-aspartate / Generic mfg.
Retrospective data, Review, Journal: Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials. (Pubmed Central) - Jun 1, 2024
This case underscores the importance of raising awareness among physicians, especially in areas with limited medical resources, about the significance of prompt diagnosis and appropriate symptomatic treatment in enhancing patient prognosis and quality of life. LOLA has significant beneficial effects on reversal of MHE and prevention of OHE in patients with cirrhosis compared with placebo or no intervention.
- || L-ornithine-L-aspartate / Generic mfg.
Clinical, Journal: Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study. (Pubmed Central) - May 25, 2024
HE grade & ammonia correlated positively in both groups. LOLA, regardless of administration route, has demonstrated efficacy in OHE.
- | L-ornithine-L-aspartate / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Apr 16, 2024
P4, N=140, Recruiting, Sponsor: Ain Shams University
LOLA, regardless of administration route, has demonstrated efficacy in OHE. Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jul 2024
- | L-ornithine-L-aspartate / Generic mfg.
Trial completion date, Trial primary completion date: LOLAbiome: Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (clinicaltrials.gov) - Mar 12, 2024
P4, N=55, Recruiting, Sponsor: Medical University of Graz
Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jul 2024 Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Oct 2024
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Retrospective data, Review, Journal: Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Mar 4, 2024
Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Oct 2024 The results also
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Mild post-COVID syndrome in young patients (Pubmed Central) - Jan 6, 2024
The results also An improvement in the objective findings, liver enzymes, a decrease in ammonia level, and an improvement in testing results for changes in cognitive functions were reported.
- || lactulose / Generic mfg., L-ornithine-L-aspartate / Generic mfg.
Review, Journal: A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy. (Pubmed Central) - Dec 27, 2023
In terms of RCTs, otherwise found in distinct stages of development, n = 3 target FMT and n = 1 probiotics. Although we benefit from the necessary information and technology to design novel strategies for microbiota, only probiotics and synbiotics have been extensively studied in the last decade compared to FMT.
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute overt hepatic encephalopathy- A double-blind, randomized controlled trial (Republic Ballroom) - Oct 11, 2023 - Abstract #AASLD2023AASLD_278;
All patients received lactulose...B received L-ornithine L-aspartate infusion concomitantly (p =0.3)... The addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute OHE admitted to ICU.
- | L-ornithine-L-aspartate / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Oct 3, 2023
P4, N=140, Recruiting, Sponsor: Ain Shams University
The addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute OHE admitted to ICU. Trial completion date: Aug 2023 --> Nov 2023 | Trial primary completion date: Aug 2023 --> Nov 2023
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Retrospective data, Review, Journal: Primary prevention of hepatic encephalopathy post-TIPS: A systematic review and meta-analysis. (Pubmed Central) - Sep 25, 2023
A rifaximin and lactulose combination therapy may be beneficial. Overall, there is significant limitation in the current data and more studies are needed to yield more robust meta-analysis results in the future.
- L-ornithine-L-aspartate / Generic mfg.
Efficacy of L-Ornithine L-Aspartate as a Stand-Alone Treatment for Hepatic Encephalopathy in Patients With Cirrhosis - A Systematic Review and Meta-Analysis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2873;
Pooled data on the effects of LOLA as a stand-alone therapy on mental status improvement was assessed and showed significant benefit over placebo (Relative risk: 1.32, 1.12-1.55, I 2 = 67%, p< 0.01). The improvement in mental status was evaluated by psychometric testing and/or West Haven Criteria, and reduction to at least one grade of hepatic encephalopathy from the presentation was included.
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Retrospective data, Review, Journal: Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: A systematic review and meta-analysis. (Pubmed Central) - Jul 28, 2023
However when compared to lactulose and LOLA, probiotics did not show a significant difference in reversal of MHE or reduction of serum ammonia levels. Probiotics were more effective in reversal of MHE and reduced serum ammonia levels in patients with MHE compared to placebo or no treatment, but not more effective than lactulose or LOLA.
- | L-ornithine-L-aspartate / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Jul 21, 2023
P4, N=140, Recruiting, Sponsor: Ain Shams University
Probiotics were more effective in reversal of MHE and reduced serum ammonia levels in patients with MHE compared to placebo or no treatment, but not more effective than lactulose or LOLA. Trial completion date: May 2023 --> Aug 2023 | Trial primary completion date: May 2023 --> Aug 2023
- L-ornithine-L-aspartate / Generic mfg.
RANDOMIZED COMPARATIVE STUDY TO ASSESS THE EFFICACY OF INJECTABLE L-ORNITHINE L-ASPARTATE VERSUS ORAL L-ORNITHINE L-ASPARTATE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOSIS (Poster Stage 2) - Jul 8, 2023 - Abstract #UEGW2023UEGW_287;
- | L-ornithine-L-aspartate / Generic mfg.
New P4 trial: Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy (clinicaltrials.gov) - Jun 27, 2023
P4, N=360, Not yet recruiting, Sponsor: Jinnah Postgraduate Medical Centre
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Valproate-induced hyperammonemic encephalopathy treated by L-ornithine-L-aspartate: a case report. (Pubmed Central) - May 31, 2023
He was rceiving antiepileptic treatment of continuously intravenously pumped sodium valproate of 64 mg/h for 4 days, which overlapped for 12 hours with taking 500 mg sustained release tablets...The patient was also being treated with ceftriaxone sodium for a hypostatic pneumonia and with desmopressin for diabetes insipidus...Immediate recognition of the serious but uncommon adverse effects is essential. To our knowledge this is the first report of ornithine aspartate being used in this disorder.
- L-ornithine-L-aspartate / Generic mfg.
Efficacy of arginine glutamate injection for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: a randomized controlled trial (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_437;
0.020 49 47(95.9) 3.5%?-5.6%, 12.5%? 0.0015 control group 54 49(90.7) 53 49(92.4) Non-inferiority margin=-15.0% javascript:; javascript:; javascript:;
- | L-ornithine-L-aspartate / Generic mfg.
New trial: Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure. (clinicaltrials.gov) - Mar 21, 2023
P=N/A, N=32, Not yet recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
- || lactulose / Generic mfg., Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, L-ornithine-L-aspartate / Generic mfg.
Very much the kitchen sink version… added to lactulose and rifaximin. It is branded as Hepamerz for U.K. (Twitter) - Mar 11, 2023
- | lactulose / Generic mfg., Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, L-ornithine-L-aspartate / Generic mfg.
Journal: Hepatic encephalopathy - recent advances in treatment and diagnosis. (Pubmed Central) - Mar 3, 2023
Other agents (including branched-chain amino acids, probiotics, other antibiotics, or intravenous L-ornithine L-aspartate) are available, but the evidence supporting their efficacy remains under debate. Gray areas and future needs remain the therapeutic approach to MHE and issues in the design of therapeutic studies for HE which have been extensively discussed in this review.
- | L-ornithine-L-aspartate / Generic mfg.
New P4 trial: LOLAbiome: Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (clinicaltrials.gov) - Feb 21, 2023
P4, N=55, Recruiting, Sponsor: Medical University of Graz
- | L-ornithine-L-aspartate / Generic mfg.
New P4 trial: Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease) Eine Beobachtungsstudie zur Wirkung von L-Ornithin-L-Aspartat (LOLA) auf die Darmflora von Patienten mit Leberzirrhose (Sch (EUDRACT) - Jan 26, 2023
P4, N=55, Ongoing, Sponsor: CBmed GmbH
- | Primaxin (cilastatin/imipenem) / Abbott
Journal: Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report. (Pubmed Central) - Dec 23, 2022
Ureaplasma parvum could cause septic arthritis with hyperammonemia. Genetic tests, such as polymerase chain reaction and next-generation sequencing techniques, could provide a sensitive and fast diagnosis of Ureaplasma parvum.
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. (Pubmed Central) - Dec 6, 2022
Our study confirms the perturbation of hepatic ammonia detoxification pathways in NASH. Results from the interventional experiments suggest a direct beneficial impact of LOLA on skeletal muscle during NASH development, though it does not improve ammonia metabolism or liver disease.
- | L-ornithine-L-aspartate / Generic mfg.
Enrollment open: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Nov 7, 2022
P4, N=140, Recruiting, Sponsor: Ain Shams University
Results from the interventional experiments suggest a direct beneficial impact of LOLA on skeletal muscle during NASH development, though it does not improve ammonia metabolism or liver disease. Not yet recruiting --> Recruiting
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. (Pubmed Central) - Oct 22, 2022
Not yet recruiting --> Recruiting No abstract available
- | L-ornithine-L-aspartate / Generic mfg.
Journal: L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson's Disease Models. (Pubmed Central) - Oct 1, 2022
Moreover, by increasing NCXs expression and activity, LOLA also reduced cytosolic [Ca] thanks to its ability to modulate NO production. Collectively, these results indicate that LOLA, by interfering with those mitochondrial mechanisms related to ROS and RNS production, promotes mitochondrial functional recovery, thus confirming the tight relationship existing between cytosolic ionic homeostasis and cellular metabolism depending on the type of insult applied.
- | L-ornithine-L-aspartate / Generic mfg.
New P4 trial: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Sep 14, 2022
P4, N=140, Not yet recruiting, Sponsor: Ain Shams University
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate. (Pubmed Central) - Aug 18, 2022
The results showed that ammonia poisoning could induce serum ammonia content elevated, liver damage (serum aminotransferase activity elevated and liver malondialdehyde accumulation), and up-regulation of cytokine (IL 1, IL 8 and TNFÉ‘), apoptosis (P53, Bax, Cytochrome c, Caspase 3 and Caspase 9) and autophagy (Dynein, Beclin 1, AKT and PTEN) genes transcription, but LoLa could mitigate the adverse effect of ammonia poisoning. Our results suggesting that LoLa can detoxify ammonia into glutamine and stores it in muscle.
- || aspirin / Generic mfg., L-ornithine-L-aspartate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Review, Journal: Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. (Pubmed Central) - Jul 27, 2022
Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non-antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
- || L-ornithine-L-aspartate / Generic mfg.
Review, Journal: Management of Portal Hypertension. (Pubmed Central) - Jul 13, 2022
In this review, we discuss the diagnosis and management of cirrhosis-related portal hypertension in detail. Also, we highlight the history of portal hypertension and future research areas in portal hypertension.
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Review, Journal: Evidence-based approach to management of hepatic encephalopathy in adults. (Pubmed Central) - Jun 4, 2022
There are many therapeutic agents available for the management of HE, most of which are directed towards lowering the gut nitrogen load and thus the serum ammonia level. This review aims to provide an update on the conventional and emerging treatment options for HE.
- | L-ornithine-L-aspartate / Generic mfg.
Journal: Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis? (Pubmed Central) - May 6, 2022
This review aims to provide an update on the conventional and emerging treatment options for HE. No abstract available
- || L-ornithine-L-aspartate / Generic mfg.
Clinical, Journal: "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial". (Pubmed Central) - Apr 27, 2022
No abstract available Combination of LOLA with lactulose and rifaximin was more effective than only lactulose and rifaximin in improving grades of HE, recovery time from encephalopathy, with lower 28-day mortality.
- | L-ornithine-L-aspartate / Generic mfg.
Preclinical, Journal: Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity. (Pubmed Central) - Apr 5, 2022
A subset of young mice was subjected to ammonia lowering treatment by L-ornithine L-aspartate (LOLA)...These findings suggest that the occurrence of NASH precedes sarcopenia in HFD mice, and the steatohepatitis-related hyperammonemia might contribute to the pathogenesis of sarcopenia. LOLA might be an effective drug for both steatohepatitis and sarcopenic obesity.
- L-ornithine-L-aspartate / Generic mfg.
Intrahepatic microcirculation disorders and hyperammoniemia and their correction at nonalcoholic steatohepatitis patients with initial stages of liver fibrosis (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1696;
NASH is accompanied by disorders of intrahepatic microcirculation disorders in out flow zone. LOLA improved liver microcirculation and decreases of blood ammonia level at the NASH and HCV patients.
- | L-ornithine-L-aspartate / Generic mfg.
Retrospective data, Journal: Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis. (Pubmed Central) - Mar 5, 2022
A higher abundance of Flavonifractor and Oscillospira in LOLA-treated patients could indicate LOLA as a potential microbiome modulating strategy in patients with liver disease. The lower levels of IGF1 in patients treated with LOLA suggest a possible link between the pathophysiology of hepatic encephalopathy and muscle health.
- L-ornithine-L-aspartate / Generic mfg.
L-ornithine L-aspartate in acute treatment of severe Hepatic encephalopathy: A double-blind randomized controlled trial (101+102, 1F) - Feb 24, 2022 - Abstract #APASL2022APASL_713;
- || Ravicti (glycerol phenylbutyrate) / Horizon Therapeutics, Immedica
Review, Journal: Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis. (Pubmed Central) - Oct 27, 2021
Effective lowering of circulating ammonia is the mainstay strategy in the prevention and treatment of hepatic encephalopathy in cirrhosis and there is increasing interest in agents with the metabolic potential for the active removal of ammonia by the liver and skeletal muscle by agents including L-ornithine L-aspartate, branched-chain amino acids, as well as the re-purposing of benzoate and phenylacetate currently employed for the control of hyperammonaemia in congenital urea-cycle enzymopathies...Glycerol phenylbutyrate was the only agent with a beneficial effect on both hyperammonaemia and hepatic encephalopathy. None were superior to lactulose for the lowering of blood ammonia.
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Clinical, Review, Journal: Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. (Pubmed Central) - Oct 27, 2021
In addition, rifaximin treatment was better than other active drugs in improving psychometric indicators (mental state, flapping tremor and portosystemic encephalopathy (PSE) index) and reducing the risk of rehospitalization in HE patients. Rifaximin therapy is effective and well-tolerated in different types of HE, which might be recommended as an alternative to conventional oral drugs in clinical settings.